Although the efficacy and safety of the factor Xa inhibitor for the prevention of VTE and stroke in patients with NVAF were shown in global clinical trials, the safety and effectiveness data from unselected patients in everyday clinical practice are yet limited. The gene discussed is F10; the disease is stroke disorder.